PT. RICHMOND, Calif., Feb. 7 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the 10th Annual BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 12, 2008 at 10:15 AM Eastern Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. Transcept
development projects leverage new understanding of CNS conditions to
provide additional uses and enhanced clinical benefits for existing active
agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate
lozenge), is a low dose sublingual formulation of zolpidem for the
treatment of insomnia in patients who awaken in the middle of the night and
have difficulty returning to sleep. Phase 3 clinical trials have been
completed for Intermezzo(R) and Transcept plans to submit an NDA in the
third quarter of 2008. Another product being developed by Transcept is
TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for
the treatment of dopamine associated psychiatric disorders. TO-2060 has
recently completed a successful dose ranging trial for the treatment of
alcohol use disorder and a full clinical development program has begun. For
further information, please visit the company's website at:
http://www.transcept.com.
Contacts:
Transcept Pharmaceuticals, Inc.
Michael Gill
Director of Communications
(510) 215-3575
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
SOURCE Transcept Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |